Bionomics (BNO)

Download button icon Download

Bionomics (BNO): Signals

No data currently available.

data-ad-format="auto">

Explore Compare Share

TECHNICAL ANALYSIS SUMMARY

Bionomics (BNO.AX)


Indicator:

TRIANGULAR MOVING AVERAGE


Last Signal:

BULLISH


Trading: BUY @ $0.12
Signal Strength: STRONG
Recommendation:

Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has the ability to highlight trends across numerous timeframes. This indicator has the ability to smooth historical results to illustrate trend initiation and status. Although this is a simple trend following indicator & can provide good results when coupled with the right indicator. Note, this indicator does not work well in ranging markets producing unwanted whipsaws and false signals.


Bionomics (ASX:BNO) currently has a confirmed uptrend. Recent trading has caused the TMA 15 day average to exceed the closing price confirming the short term trend following indicator. Currently, the return on TMA15 is -4.0%.



A triangular moving average can be calculated using various input data such as prices volume or another technical indicator.

Calculation: Triangular Moving Average (TMA):
1) SMA: n period sum / n;
2) TMA = (n SMA period sum) / N;


PROFILE: Bionomics (BNO.AX)


Stock Exchange: ASX
Company: Bionomics
Ticker Codes: | BNO.AX | ASX:BNO |

About Bionomics (ASX:BNO):

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancer in Australia, France, and the United States. It operates through Drug Discovery and Development, and Contract Services segments. The company's product pipeline includes BNC210, a novel and proprietary negative allosteric modulator, which is in Phase II clinical trial for the treatment of generalized anxiety disorder, as well as is in the initiation of a Phase II clinical trial in patients with post-traumatic stress disorder; BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that targets cancer stem cells; and BNC105, a vascular disrupting agent for the treatment of cancer, as well as disrupts the blood vessels that nourish tumors in cancer treatment. It also offers contract research services. The company has partnerships with Merck & Co., Inc.; Cancer Therapeutics Cooperative Research Centre; Genmab A/S; Laboratory Corporation of America (LabCorp); Athena Diagnostics; and Genetic Technologies Limited. Bionomics Limited was founded in 1998 and is based in Thebarton, Australia.

Top 10:

Triangular Moving Average

Download button icon Download
Company Close Change (%) Volume Value Signal
EMH European Metals Holdings 0.4 25 64,019 31.1 BULLISH
CLQ Clean Teq Holdings 0.5 12.4 2,443,784 27.9 BULLISH
FBR Fastbrick Robotics 0.12 9.1 8,397,122 18.8 BULLISH
MOY Millennium Minerals 0.21 7.9 2,367,754 12.6 BULLISH
VTG Vita 1.16 6.9 644,761 9.5 BULLISH
IRI Integrated Research 2.3 5 2,143,070 33.2 BULLISH
SXY Senex Energy 0.33 4.8 7,225,917 7.6 BULLISH
AVJ Av Jennings Homes 0.58 4.5 231,276 10.1 BULLISH
WHC Whitehaven Coal 4.71 3.7 11,605,718 7.3 BULLISH
MNY Money3 1.72 3.6 353,313 7.2 BULLISH
back to top